Laura C. Godfrey

Oxford, ENG OX39DS, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

p300/CBP is an essential driver of pathogenic enhancer activity and gene expression in Ewing sarcoma.

p300/CBP is an essential driver of pathogenic enhancer activity and gene expression in Ewing sarcoma.

Journal: EMBO reports
Published: October 04, 2024

MLL-AF4 cooperates with PAF1 and FACT to drive high-density enhancer interactions in leukemia.

MLL-AF4 cooperates with PAF1 and FACT to drive high-density enhancer interactions in leukemia.

Journal: Nature communications
Published: December 08, 2022

Viewing AML through a New Lens: Technological Advances in the Study of Epigenetic Regulation.

Viewing AML through a New Lens: Technological Advances in the Study of Epigenetic Regulation.

Journal: Cancers
Published: November 01, 2022

MLL::AF9 degradation induces rapid changes in transcriptional elongation and subsequent loss of an active chromatin landscape.

MLL::AF9 degradation induces rapid changes in transcriptional elongation and subsequent loss of an active chromatin landscape.

Journal: Molecular cell
Published: May 06, 2021

Chromatin accessibility governs the differential response of cancer and T cells to arginine starvation.

Chromatin accessibility governs the differential response of cancer and T cells to arginine starvation.

Journal: Cell reports
Published: June 15, 2020

BET inhibition disrupts transcription but retains enhancer-promoter contact.

BET inhibition disrupts transcription but retains enhancer-promoter contact.

Journal: Nature communications
Published: December 14, 2019

H3K79me2/3 controls enhancer-promoter interactions and activation of the pan-cancer stem cell marker PROM1/CD133 in MLL-AF4 leukemia cells.

H3K79me2/3 controls enhancer-promoter interactions and activation of the pan-cancer stem cell marker PROM1/CD133 in MLL-AF4 leukemia cells.

Journal: Leukemia
Published: August 15, 2019

Discovery of a CD10-negative B-progenitor in human fetal life identifies unique ontogeny-related developmental programs.

Discovery of a CD10-negative B-progenitor in human fetal life identifies unique ontogeny-related developmental programs.

Journal: Blood
Published: November 29, 2018

DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation.

DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation.

Journal: Nature communications
Published: August 14, 2018

MLL-AF4 binds directly to a BCL-2 specific enhancer and modulates H3K27 acetylation.

MLL-AF4 binds directly to a BCL-2 specific enhancer and modulates H3K27 acetylation.

Journal: Experimental hematology
Published: July 27, 2016

MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia.

MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia.

Journal: Cell reports
Published: June 22, 2016

MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199.

MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199.

Journal: Cell reports
Published: May 07, 2015
Showing 1-12 of 12

Last Updated: 09/26/2026